DJIA 17,001.22 -38.27 -0.22%
NASDAQ 4,538.55 6.45 0.14%
S&P 500 1,988.40 -3.97 -0.20%
market minute promo

VIVUS, Inc. (NASDAQ: VVUS)

4.20 0.00 (0.00%)

REAL-TIME: Last trade at

Extended Hours: $4.20 $0.00 (0.00%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

VVUS $4.20 0.00%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $4.20
Previous Close $4.20
Daily Range $4.12 - $4.23
52-Week Range $4.06 - $12.95
Market Cap $434.5M
P/E Ratio -4.04
Dividend (Yield) $0.00 (0.0%)
Volume 677,652
Average Daily Volume 1,392,375
Current FY EPS -$0.97

Sector

Healthcare

Industry

Drugs

VIVUS, Inc. (VVUS) Description

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products. Website: http://www.vivus.com/

News & Commentary

The Implications of Obesity as a Disability in Europe

Despite rising obesity in Europe, the EU has yet to approve weight loss drugs from Arena (ARNA), Vivus (VVUS), or Orexigen (OREX).

Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind

Arena And VIVUS: A Case Study In Small-Cap Pharma

Belviq Sales Flatten Out But Edge Above Qsymia

FDA Data: Good News For One Anti-Obesity Company, Not So Good For Another

The 52-Week Low Club for Wednesday

Auxilium Posts Wider-than-Expected Loss, Outlook Maintained - Analyst Blog

Auxilium Posts Wider-than-Expected Loss, Outlook Maintained - Analyst Blog

VIVUS Reports Narrower-than-Expected Loss on Qsymia Sales - Analyst Blog

Arena's Belviq Bucks Seasonality With 3.6% Week Over Week Gain

Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount - Analyst Blog

Vivus Beats The Street - Still Has A Loss

See More VVUS News...

VVUS's Top Competitors

VVUS $4.20 (0.00%)
Current stock: VVUS
JNJ $103.10 (-0.38%)
Current stock: JNJ
PFE $28.92 (0.35%)
Current stock: PFE
NVS $88.95 (0.00%)
Current stock: NVS